Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
Journal of the American Society of Nephrology ; 33:313, 2022.
Article in English | EMBASE | ID: covidwho-2125753


Background: This study aimed to evaluate the immunogenicity of two doses of ChAdOx1 nCoV-19 and the immune response post-COVID-19 infection in ESRD with HD patients. Method(s): The blood samples were obtained at baseline, 1-month, and 3-month follow-up after each shot or recovery. All participants were measured for anti-spike IgG by the ELISA method using Euroimmun. Result(s): This study found a significant increase in anti-spike IgG after 1 month of two-shot ChAdOx1 nCoV-19 vaccination, followed by a significant decrease after 3 months. On the other hand, the anti-spike IgG was maintained in the post-recovery group. There was no significant difference in the change of anti-spike IgG between oneshot ChAdOx1 nCoV-19 vaccinated and post-recovery groups for both 1-month and 3-month follow-ups. The seroconversion rate for the vaccinated group was 60.32% at one-month after one-shot vaccination and slightly dropped to 58.73% at 3-month followup, then was 92.06% at one-month after two-shot vaccination and reduced to 82.26% at 3-month follow-up. For the recovered group, the seroconversion rate was 95.65% at one-month post-recovery and 92.50% at 3-month follow-up. Conclusion(s): This study established the immunogenicity of two-shot ChAdOx1 nCoV-19 in ESRD patients with HD for humoral immunity. After COVID-19 infection, the humoral immune response was strong and could be maintained for at least three months.

Virologie ; 26(2):181, 2022.
Article in English | EMBASE | ID: covidwho-1912989


Several COVID-19 vaccines have now been deployed to tackle the SARSCoV- 2 pandemic, most of them based on messenger RNA or adenovirus vectors. The duration of protection afforded by these vaccines is unknown, as well as their capacity to protect from emerging new variants. To provide sufficient coverage for the world population, additional strategies need to be tested. The live pediatric measles vaccine (MeV) is an attractive approach, given its extensive safety and efficacy history, along with its established large-scale manufacturing capacity. We develop an MeVbased SARS-CoV-2 vaccine expressing the prefusion-stabilized, membrane-anchored full-length S antigen, which proves to be efficient at eliciting strong Th1-dominant T-cell responses and high neutralizing antibody titers. In both mouse and golden Syrian hamster models, these responses protect the animals from intranasal infectious challenge. Additionally, the elicited antibodies efficiently neutralize in vitro the three currently circulating variants of SARS-CoV-2.